NCT00780104View on ClinicalTrials.gov

Sirolimus in Combination With MEC in High Risk Myeloid Leukemias

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

June 30, 2010

Conditions
Myeloid LeukemiasAMLLeukemiaCML
Interventions
DRUG

Rapamycin, Mitoxantrone, Etoposide, Cytarabine

Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.

DRUG

Rapamycin + MEC

Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.

Trial Locations (1)

19104

University of Pennsylvania Abramson Cancer Center, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT00780104 - Sirolimus in Combination With MEC in High Risk Myeloid Leukemias | Biotech Hunter | Biotech Hunter